Ahmad Awada

Research interests

Publications

• Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30068-1

• A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

  Clinical Cancer Research · 2020 · 10.1158/1078-0432.ccr-20-1764

• Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial

  Carolina Digital Repository (University of North Carolina at Chapel Hill) · 2020 · 10.17615/tfn3-9835

• MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

  npj Breast Cancer · 2019 · https://doi.org/10.1038/s41523-018-0097-z

• Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2016.71.3495

• Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy517

• Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.78.2292

• Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30106-2

• Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30376-5

• Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer

  JAMA Oncology · 2016 · 10.1001/jamaoncol.2016.0237

• Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

  Annals of Oncology · 2015 · https://doi.org/10.1093/annonc/mdv577

• Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2013.52.4892

• Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

  Breast Cancer Research and Treatment · 2014 · 10.1007/s10549-014-3144-y

• Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer

  Annals of Oncology · 2014 · 10.1093/annonc/mdu288

• Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.46.2408

• Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70335-2

• Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2009.25.8467

• Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2009.25.8707

• Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

  New England Journal of Medicine · 2007 · https://doi.org/10.1056/nejmoa071028

• Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers

  The Oncologist · 2007 · 10.1634/theoncologist.12-12-1443

• Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors

  The Oncologist · 2007 · 10.1634/theoncologist.12-4-426

• Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

  Clinical Cancer Research · 2006 · 10.1158/1078-0432.ccr-05-1571

• Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

  British Journal of Cancer · 2005 · 10.1038/sj.bjc.6602584

• Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

  Journal of Clinical Oncology · 2004 · https://doi.org/10.1200/jco.2005.06.124

• Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over

  Journal of Clinical Oncology · 2000 · 10.1200/jco.2000.18.4.724

Current projects

No projects listed.